CFH rs191281603: Rare Variant and Macular Health
The rs191281603 variant is a rare coding alteration located within the CFH gene on chromosome 1. It is statistically implicated in individual susceptibility to age-related macular changes, including choroidal neovascularization and macular tissue damage. Because it occurs at very low frequencies in global populations, research on its clinical impact remains limited.
What each genotype means
Typical risk profile
You carry two copies of the common reference allele at this CFH position. This genotype has not been associated with altered complement factor H activity or an increased risk of macular neovascularization. It reflects the standard baseline risk seen in the general population.
Carried by more than 99.6% of individuals across all major global populations.
Modestly increased susceptibility risk
You carry one copy of the rare variant allele in the complement factor H gene, which has been identified in genomic studies as an independent risk marker for advanced age-related macular changes and choroidal neovascularization. Because this is a rare variant with limited functional data, clinical evidence regarding its exact individual effect remains constrained, and having this allele does not mean you will develop macular disease.
Carried by fewer than 0.4% of individuals globally, primarily identified at low frequencies in European cohorts.
Homozygous rare variant
You carry two copies of this rare complement factor H variant. Due to the extreme scarcity of the minor allele, research on individuals homozygous for this variant is virtually absent, leading to significant scientific uncertainty regarding its precise physiological impact. Existing association models suggest a possible increased susceptibility to complement-mediated macular damage, but this genotype is not clinically diagnostic.
Extremely rare; observed in far fewer than 1 in 100,000 individuals globally.
Genetic Architecture of rs191281603 and the CFH Locus
The rs191281603 single nucleotide polymorphism is positioned in the CFH (complement factor H) gene on chromosome 1. The CFH locus is a critical genomic region known for housing multiple common and rare genetic variations that influence immune homeostasis. While common polymorphisms like Y402H have been studied extensively, rs191281603 represents an uncommon single nucleotide change identified via targeted and exome sequencing efforts. Because it resides in a region coding for structural protein domains, alterations at this locus can influence how complement regulatory proteins fold or interact with biological surfaces.
The Biological Role of Complement Factor H
Complement factor H (CFH) is a major circulating glycoprotein that serves as a vital negative regulator of the alternative complement pathway. Part of the innate immune system, the complement cascade defends the host against pathogens and clears cellular debris. However, uncontrolled complement activation can attack healthy host tissues. Factor H binds to host cells via specific surface glycosaminoglycans and sialic acid markers, inactivating C3b to prevent unnecessary inflammation and tissue destruction. Disruptions in CFH balance can leave specialized tissues, such as the renal microvasculature and retinal pigment epithelium, vulnerable to chronic inflammatory injury.
Research Associations with Macular Degeneration and Choroidal Damage
Large-scale genetic studies and genome-wide analyses examining advanced age-related macular degeneration (AMD) have identified rs191281603 as one of several independent signals within the extended CFH and CFHR locus. Specifically, research evaluating advanced retinal pathology associates variants in this pathway with choroidal neovascularization, a severe process where abnormal, fragile blood vessels sprout underneath the retina, leading to fluid leakage and macular damage. However, because rs191281603 is a low-frequency variant, statistical evidence regarding its isolated effect size remains limited and is largely evaluated as part of multi-variant complement risk scores or locus-wide conditioned analyses.
Population Frequency and Genetic Rarity
According to population databases such as the Genome Aggregation Database (gnomAD), rs191281603 is a rare variant, exhibiting an overall minor allele frequency of less than 0.2% across global populations. The vast majority of individuals worldwide carry two copies of the reference allele. Because it appears infrequently, homozygosity for the minor allele is exceptionally rare. Genomic research notes that representation of rare variants can vary across specific ancestral groups, and continued multi-ancestry sequencing is necessary to establish precise distribution figures across non-European cohorts.
Practical Interpretation and Clinical Context
Learning one's genotype at rs191281603 provides exploratory insight into innate immune regulation, but it does not represent a medical diagnosis. Genetic variants in CFH confer probabilistic susceptibility rather than deterministic outcomes. Having a risk-associated allele does not guarantee the development of macular neovascularization, nor does carrying standard alleles guarantee immunity from retinal disorders. Environmental lifestyle factors, including smoking status, diet, and age, play substantial roles in macular health. Anyone experiencing changes in vision or curious about familial eye disease should consult an eye care specialist or certified genetic counselor.
How common is this variant?
The rs191281603 polymorphism is a rare variant with a minor allele frequency of less than 0.2% globally in gnomAD, with the overwhelming majority of all ancestral populations homozygous for the common reference allele.
Frequently asked questions
What does a rare variant like rs191281603 mean for my eye health?
Carrying a rare variant in CFH means you have a genetic change that researchers have linked to subtle differences in complement regulation. It suggests a possible statistical susceptibility to macular changes, but it does not mean you will develop vision loss or macular degeneration.
Does rs191281603 cause choroidal neovascularization on its own?
No, rs191281603 does not directly cause choroidal neovascularization by itself. Advanced retinal conditions are complex traits influenced by multiple genetic loci, advancing age, cardiovascular health, and environmental factors like smoking.
Can routine genetic testing detect rs191281603?
Because rs191281603 is a rare variant, it is often missed by standard consumer genotyping arrays that focus primarily on common markers. It is typically detected only via high-density arrays, exome sequencing, or whole-genome sequencing.
What actions should I take if I carry an atypical CFH genotype?
Genetic results should be used for personal awareness rather than self-treatment. Scheduling regular comprehensive eye examinations, refraining from smoking, and discussing any family history of retinal disease with an optometrist or ophthalmologist are the most effective steps.
Sources & further reading
Educational information only, last refreshed 9/13/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs191281603?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in CFH
This variant in the complement factor H gene is associated with altered regulation of the alternative complement pathway and increased susceptibility to age-related macular degeneration.
This regulatory variant in the CFH locus is linked to complement system dysregulation and is a recognized genetic risk factor for age-related macular degeneration.
Intronic single nucleotide variant in the CFH region associated with susceptibility to age-related macular degeneration (AMD).
Common variant in the CFH locus strongly associated with risk of age-related macular degeneration (AMD).
Genomic marker in CFH frequently co-inherited in haplotypes modulating risk of late-stage visual loss from macular degeneration.
Intronic marker in CFH forming critical susceptibility haplotypes for choroidal neovascularization and macular atrophy.